Back to Interventions
Substance / Medication

Nusinersen

SNOMED 723985005UMLS C4301236

Overview

Active Ingredient
nusinersen
RxNorm CUI
1863556

Indications

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Labeler: Biogen Inc.Updated: 2025-11-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Spinal muscular atrophy

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Recent Trials

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

NCT04488133Phase 4Completed46 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy.
Hagenacker Tim, Paradis Angela D, Lawson-Michod Katherine A et al. · Adv Ther · 2025
PMID: 40576875Meta-AnalysisFull text (PMC)
Surgical success of subcutaneous systems for intrathecal nusinersen delivery in spinal muscular atrophy: A systematic review and meta-analysis.
Lu Victor M, Vazquez Sima, Roach Caleigh S et al. · Clin Neurol Neurosurg · 2025
PMID: 40743658Meta-Analysis
Motor Function and Safety of Nusinersen and Risdiplam in Asian Patients with Types 2-4 Spinal Muscular Atrophy (SMA): A Systematic Review and Meta-Analysis.
Zhao Xinran, Liao Yihan, Zhao Jingyu et al. · Adv Ther · 2025
PMID: 39960588Meta-Analysis
The Impact of Nusinersen and Risdiplam on Motor Function for Spinal Muscular Atrophy Type 2 and 3: A Meta-Analysis.
Chen Bo, Gong Yuanlin, Zhou Tengteng · J Coll Physicians Surg Pak · 2024
PMID: 39113515Meta-Analysis
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
Giess Doris, Erdos Judit, Wild Claudia · Eur J Paediatr Neurol · 2024
PMID: 38905882Meta-Analysis
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2022,, 213.
Aljabali Ahmed, Abdo Maha, Negida Ahmed · Medicina (Kaunas) · 2022
PMID: 35744029Meta-AnalysisFull text (PMC)
Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2022,, 213".
Abdelazeem Basel, Abbas Kirellos Said, Brašić James Robert · Medicina (Kaunas) · 2022
PMID: 35744055Meta-AnalysisFull text (PMC)
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abbas Kirellos Said, Eltaras Mennatullah Mohamed, El-Shahat Nahla Ahmed et al. · Medicina (Kaunas) · 2022
PMID: 35208537Meta-AnalysisFull text (PMC)
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
Erdos Judit, Wild Claudia · Eur J Paediatr Neurol · 2022
PMID: 35533607Meta-Analysis
Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
Gavriilaki Maria, Moschou Maria, Papaliagkas Vasileios et al. · Neurotherapeutics · 2022
PMID: 35178673Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nusinersen (substance)
SNOMED CT
723985005
UMLS CUI
C4301236
RxNorm CUI
1863556
Labeler
Biogen Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.